Financials
Reported figures only · latest: Q4 2025
USD · IFRS
Source: SEC XBRL filings
· latest filing
The long view
Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income7 fiscal yearsShow the numbers
| Year | Revenue | Net income |
|---|
| FY25 | $586.3M | $27.9M |
|---|
| FY24 | $489.7M | −$231.9M |
|---|
| FY23 | $91.4M | −$551.7M |
|---|
| FY22 | $83M | −$513.6M |
|---|
| FY21 | $36.8M | −$101.5M |
|---|
| FY20 | $66.6M | −$170M |
|---|
| FY19 | - | - |
|---|
MarginsShare of revenue- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|
| FY25 | 59.8% | 13.3% | 4.8% |
|---|
| FY24 | 62.2% | 14.2% | −47.3% |
|---|
| FY23 | −75.9% | −388.1% | −603.4% |
|---|
| FY22 | 22.8% | −417.3% | −618.6% |
|---|
| FY21 | 100% | −640.3% | −276% |
|---|
| FY20 | - | −206.5% | −255.3% |
|---|
| FY19 | - | - | - |
|---|
Free cash flowOperating cash flow minus capital expenditureShow the numbers
| Year | Free cash flow |
|---|
| FY25 | −$114.7M |
|---|
| FY24 | −$290.5M |
|---|
| FY23 | −$345.4M |
|---|
| FY22 | −$350.3M |
|---|
| FY21 | −$248.6M |
|---|
| FY20 | −$81.8M |
|---|
| FY19 | - |
|---|
Net margin vs the sectorMedian of Healthcare companies filing with the SEC- Alvotech
- Healthcare median
Show the numbers
| Year | Alvotech | Healthcare median |
|---|
| FY25 | 4.8% | −30.6% |
|---|
| FY24 | −47.3% | −47% |
|---|
| FY23 | −603.4% | −58% |
|---|
| FY22 | −618.6% | −80.4% |
|---|
| FY21 | −276% | −71.9% |
|---|
| FY20 | −255.3% | −62.2% |
|---|
| FY19 | - | −46.3% |
|---|